Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix.
Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Galarza Fortuna G, Sayegh N, Tripathi N, Tandar C, Dal E, Li H, Swami U, Agarwal N, Maughan BL. Campbell P, et al. Among authors: thomas vm. Ther Adv Urol. 2024 Nov 8;16:17562872241293779. doi: 10.1177/17562872241293779. eCollection 2024 Jan-Dec. Ther Adv Urol. 2024. PMID: 39524157 Free PMC article.
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U. Sayegh N, et al. Among authors: thomas vm. Eur Urol Focus. 2023 Jan;9(1):106-109. doi: 10.1016/j.euf.2022.06.015. Epub 2022 Jul 11. Eur Urol Focus. 2023. PMID: 35835693
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: thomas vm. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):279-282. doi: 10.1038/s41391-023-00696-w. Epub 2023 Jul 17. Prostate Cancer Prostatic Dis. 2024. PMID: 37460732
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: thomas vm. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):357. doi: 10.1038/s41391-023-00706-x. Prostate Cancer Prostatic Dis. 2024. PMID: 37620429 No abstract available.
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations.
Narang A, Gebrael G, Jo Y, Thomas VM, Li H, Fortuna GG, Sayegh N, Tandar C, Tripathi N, Chigarira B, Srivastava A, Hage Chehade C, Nordblad B, Maughan BL, Agarwal N, Swami U. Narang A, et al. Among authors: thomas vm. Kidney Cancer. 2024 Sep 5;8(1):135-142. doi: 10.3233/KCA-240016. eCollection 2024. Kidney Cancer. 2024. PMID: 39263256 Free PMC article.
Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.
Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D. Tripathi N, et al. Among authors: thomas vm. Urol Oncol. 2022 Nov;40(11):493.e1-493.e7. doi: 10.1016/j.urolonc.2022.07.002. Epub 2022 Jul 30. Urol Oncol. 2022. PMID: 35918248
Reply by Authors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: thomas vm. Urol Pract. 2023 Oct 30:101097UPJ000000000000047102. doi: 10.1097/UPJ.0000000000000471.02. Online ahead of print. Urol Pract. 2023. PMID: 37903752 No abstract available.
64 results